Floatz logo

Dasatinib

Endometrioid Adenocarcinoma

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

18 Active assets in the Endometrioid Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Indocyanine Green
Centre Oscar Lambret
Phase 3B
Carboplatin
National Cancer Institute (NCI)
Phase 2B
Avutometinib
University of Oklahoma
Phase 2B
PATENT BLUE VIOLET
Centre Oscar Lambret
Phase 3B
Defactinib
University of Oklahoma
Phase 2B

View all 28 →

Same molecule, other indications

Dasatinib is also rated in:

B-cell acute lymphoblastic leukemiaDormant
BB
Indicative ·
70 / 100
View asset →
chronic myeloid leukemiaDormant
BB
Indicative ·
68 / 100
View asset →
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →